Technical Analysis for PRVB - Provention Bio, Inc.

Grade Last Price % Change Price Change
F 7.7419 -5.93% -0.49
PRVB closed up 2.88 percent on Monday, April 12, 2021, on 2.54 times normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical PRVB trend table...

Date Alert Name Type % Chg
Calm After Storm Range Contraction -5.93%
Lower Bollinger Band Walk Weakness -5.93%
Wide Bands Range Expansion -5.93%
Lower Bollinger Band Touch Weakness -5.93%
Oversold Stochastic Weakness -5.93%
New 52 Week Closing Low Bearish -3.23%
Expansion Breakdown Bearish Swing Setup -3.23%
Gilligan's Island Buy Setup Bullish Swing Setup -3.23%
Volume Surge Other -3.23%
Wide Range Bar Range Expansion -3.23%
Older End-of-Day Signals for PRVB ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
60 Minute Opening Range Breakdown about 4 hours ago
Fell Below Previous Day's Low about 4 hours ago
Down 5% about 5 hours ago
Lower Bollinger Band Support about 5 hours ago
2x Volume Pace about 6 hours ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.


Provention Bio, Inc. Description

Provention Bio, Inc. is a clinical-stage biopharmaceutical company that develops therapeutics targeting immune-mediated diseases. The Company aims at developing therapies for disease that include type one diabetes (T1D), Crohn’s disease, ulcerative colitis, lupus and other viral diseases. The Company’s principal product candidates include PRV-031, PRV-6527, PRV-300, PRV-3279, and PRV-0101.PRV-031 is a product candidate in its Phase III clinical trial that is developed for the interception of T1D. PRV-6527 is an oral CSF-1R inhibitor for the treatment of Crohn’s disease. PRV-300 is developed for the treatment of ulcerative colitis. PRV-3279 is developed to treat lupus disease. PRV-101 is a multivalent coxsackie virus (CVB) vaccine for the prevention of acute CVB and the prevention of the onset of T1D.


Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Immunology Disease Diabetes Autoimmune Diseases Ulcer Colitis Ulcerative Colitis Diarrhea Abdominal Pain Crohn's Disease Lupus Viral Disease Viral Diseases Immune Mediated Diseases

Is PRVB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 20.05
52 Week Low 6.36
Average Volume 1,277,885
200-Day Moving Average 13.75
50-Day Moving Average 12.72
20-Day Moving Average 11.24
10-Day Moving Average 9.79
Average True Range 0.99
ADX 34.0
+DI 10.30
-DI 45.29
Chandelier Exit (Long, 3 ATRs ) 11.17
Chandelier Exit (Short, 3 ATRs ) 9.33
Upper Bollinger Band 14.75
Lower Bollinger Band 7.73
Percent B (%b) 0.07
BandWidth 62.47
MACD Line -1.17
MACD Signal Line -0.92
MACD Histogram -0.2449
Fundamentals Value
Market Cap 464.9 Million
Num Shares 56.5 Million
EPS -0.94
Price-to-Earnings (P/E) Ratio -8.73
Price-to-Sales 0.00
Price-to-Book 6.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 9.58
Resistance 3 (R3) 9.54 9.04 9.36
Resistance 2 (R2) 9.04 8.70 9.07 9.28
Resistance 1 (R1) 8.64 8.49 8.84 8.68 9.20
Pivot Point 8.14 8.14 8.25 8.17 8.14
Support 1 (S1) 7.74 7.80 7.94 7.78 7.26
Support 2 (S2) 7.24 7.59 7.27 7.18
Support 3 (S3) 6.84 7.24 7.11
Support 4 (S4) 6.88